Basic Search  |  Summaries  |  Advanced Search

Violation Tracker Individual Record

Company: Mallinckrodt plc
Current Parent Company: Mallinckrodt
Penalty: $100,000,000
Year: 2017
Date: January 18, 2017
Offense Group: competition-related offenses
Primary Offense: price-fixing or anti-competitive practices
Secondary Offense: generic drug pay for delay
Mega-Scandal: Generic Drug Pay for Delay
Violation Description: Mallinckrodt agreed to pay $100 million as part of the settlement of litigation brought by five states (Alaska, Maryland, New York, Texas and Washington) alleging that it acted unlawfully to prevent competition for its drug H.P. Acthar Gel, which is typically used as a last resort to treat certain life-threatening diseases. Also involved in the settlement was the Federal Trade Commission, which issued its own announcement; see the Violation Tracker entry at (click here)
Level of Government: state
Action Type: agency action
Agency: Multistate Attorneys General Case
Civil or Criminal Case: civil
HQ Country of Current Parent: Ireland
Ownership Structure of Current Parent: publicly traded
Major Industry of Current Parent: pharmaceuticals
Specific Industry of Current Parent: pharmaceuticals
Source of Data: (click here)
Source Notes: If an online information source is not working, check the Violation Tracker Data Sources page for an updated link.
Current parent company note: Parent-subsidiary relationship is current as of the most recent revision listed in the Update Log.